Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded up 20.9% during trading on Thursday . The company traded as high as C$0.29 and last traded at C$0.26. 1,333,171 shares changed hands during mid-day trading, an increase of 93% from the average session volume of 689,390 shares. The stock had previously closed at C$0.22.
Hemostemix Stock Performance
The stock has a market capitalization of C$27.01 million, a P/E ratio of -15.50 and a beta of 0.20. The business has a 50-day moving average price of C$0.11 and a 200 day moving average price of C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- Where to Find Earnings Call Transcripts
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
